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ABSTRACT

ISOLATION OF MESENCHYMAL STEM CELLS DERIVED
FROM ADULT BONE MARROW AND UMBILICAL CORD
BLOOD AND THEIR POTENTIAL TO DIFFERENTIATE INTO
OSTEOBLASTS
By Andrew P. Pacitti, B.S.

A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2006

Director: Dr. Matthew J. Beckrnan
Assistant Professor, Department of Biochemistry

The demand for treatment strategies of musculoskeletal tissues is continuously
growing, especially considering the increasing number of elderly people with
degenerative diseases of the skeletal system. Despite major strides in the field of bone
regenerative medicine during the years, current therapies, such as bone grafts, still have
several limitations. Multipotent stem cells, such as mesenchymal stem cells (MSCs) are
promising candidates for tissue repair because of their differentiation potential and their
capacity to undergo extensive replication. However, isolating a homogeneous
population of MSCs from multiple sources is an area that needs to be addressed. Also,

the knowledge regarding the mechanisms and pathways that lead to the final osteogenic
differentiation is still scarce.
The following research is a feasibility study on a new isolation technique
developed by our lab. The major focus of the research will be the isolation and
characterization of mesenchymal stem cells from both adult bone marrow and umbilical
cord blood using a novel isolation method based on immunodepletion. Furthermore we
will look at the potential of these isolated MSCs to differentiate into mature, bone
producing osteoblasts.
The results of the studies showed that our novel isolation method
allowed proliferation of a homogeneous MSC population. Our irnrnunodepleted MSCs
were 99% double positive for antibodies CD44 and CD105 which are highly specific
for multipotent MSCs while cells isolated using the plastic adherence method were only
43% double positive for the two MSC-specific markers. Homogeneous MSCs were
derived from both adult bone marrow and umbilical cord blood using our isolation
method. Utilizing the techniques of confocal microscopy, von Kossa staining, and RTPCR we also show that MSCs, upon stimulation with osteogenic supplements,
differentiate into osteoblasts capable of being used for bone tissue engineering
applications.

CHAPTER 1
GENERAL INTRODUCTION

A stem cell is a special kind of cell that has a unique capacity to renew itself and
to give rise to specialized cell types. Although most cells of the body, such as heart cells
or skin cells, are committed to conduct a specific function, a stem cell is uncommitted
and remains uncommitted, until it receives a host of signals to develop into a
specialized cell. Their proliferative capacity combined with their ability to become
specialized makes stem cells unique. Stem cells that can develop into any cell type in
the body are referred to as pluripotent, because the cells have the potential to develop
almost all of the more than 200 different known cell types [I]. Stem cells have the
ability to act as a repair system for the body, because they can divide and differentiate,
replenishing other cells as long as the host organism is alive.

Stem Cell Populations in Embryos and Adults
Embryonic Stem Cells
Embryonic stem (ES) cells are cells that are undifferentiated but have the
capacity to differentiate into all adult tissues. ES cells can be cultured for extended
periods and genetically manipulated without loss of their pluripotential capacity, as
assessed by their ability to participate in all aspects of the development of the embryo
proper when reintroduced in vivo [2]. ES cells can be induced to differentiate in vitro
into two-or three-dimensional (embryoid bodies) cultures containing cells from all three

embryonic lineages (ectoderm, mesoderm, and endoderm), including cells of the
hematopoietic [3], endothelial [4], cardiac [5,6], and neuronal [7, 81 tissues [9].

Tissue-SpecificStem Cells

Hematopoietic Stem Cells (HSCs)
A hematopoietic stem cell is a cell isolated from the blood or bone marrow that
can renew itself, can differentiate to a variety of specialized cells, can migrate out of the
bone marrow into circulating blood, and can undergo programmed cell death, called
apoptosis-a

process by which cells that are detrimental or unneeded self-destruct.

HSCs are responsible for forming the immune cells and the constant renewal of the
blood by producing billions of new blood cells each day. Experimental evidence
supporting the existence of such cells was first provided by Till &McCulloch [lo], who
injected lethally irradiated mice with bone marrow-derived cells from healthy syngenic
(genetically identical) donors and observed the formation in the spleen of multilineage
colonies that could be shown to be derived from single injected cells. Subsequent
experiments utilizing genetic marking have demonstrated that long-term engraftment of
both the lymphoid and myeloid lineages can be achieved by the progeny of a single cell
[ l 1, 121. In addition, the ability to repopulate multiple secondary recipients with the
progeny of a single clone, along with their extensive amplification when limiting
numbers are transplanted, has demonstrated that these very primitive cells are capable
of extensive (>1000-fold) in vivo amplification [ 13, 141.

Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells, also known as marrow stromal cells or mesenchymal
progenitor cells, are defined as self-renewable, multipotent progenitor cells with the
capacity to differentiate into several distinct mesenchymal lineages [15]. To date,
MSCs of multiple adult vertebrate species have been demonstrated to differentiate into
lineage-specific cells that form bone, cartilage, fat, tendon, and muscle tissue [16- 181.

In addition to differentiation into their natural derivatives, MSCs have the potential to
differentiate into other types of tissue-forming cells such as hepatic, renal, cardiac, and
neural cells. The descriptive terms "pluripotent" or "multipotent" are reciprocally used
to describe the capacity of MSCs to differentiate into a wide arrange of mammalian
tissues [19].

Sources of Mesenchymal Stem Cells
Bone Marrow
Bone marrow is a complex tissue comprised of hematopoietic precursors, their
differentiated progeny, and a connective tissue network referred to as stroma. The
stroma itself is a heterogeneous mixture of cells including adipocytes, reticulocytes,
endothelial cells, and fibroblastic cells which are in direct contact with the
hematopoietic elements [20]. Since it has been well established that the stroma contains
cells that differentiate into bone, cartilage, fat, and a connective tissue which supports
the differentiation of hematopoietic stem cells [21-231, identification of the progenitor
cells for these mesenchymal tissues has been an area of active investigation.

Friedenstein [24] and others [25-271 have demonstrated that culture-adherent cells
present in the marrow stroma are capable of differentiating into bone and cartilage when
placed into an appropriate environment in vivo. These experiments have led to the
hypothesis that stroma contains a unique population of stem cells which are capable of
differentiating along multiple mesenchymal cell lineages [15,26,27].
Currently, bone marrow (BM) represents the main source of MSCs for both
experimental and clinical studies [18,28,29], but aspirating bone marrow from the
patient is an invasive procedure and, in addition, it has been demonstrated that the
number and the differentiating potential of bone marrow MSCs decreases with age [30].
Therefore, it can be argued that cells with both extensive potency of proliferation and
differentiation would represent an optimal tool for future cell-based therapeutic
applications.

Umbilical Cord Blood
Umbilical cord blood (UCB) has turned out to be an excellent alternative source
of hematopoietic stem cells (HSCs) for clinical-scale allogenic transplantation [311.
Cord blood represents a relatively rich source of otherwise discarded HSCs and 80ml
can reconstitute the hematopoietic system in small patients, usually children, although
there are some reports of successful transplantation of adults [32,33]. Cord blood has a
reduced risk of graft versus host disease (GVHD) compared with bone marrow in both
HLA-matched and mismatched HSC transplants, due to naivet6 of T lymphocytes in
cord blood [34]. Since the first successful related cord blood transplant 16 years ago,

the efficacy of cord HSCs has been demonstrated in over 2000 unrelated and related
cord blood transplants worldwide, even in cases of incomplete tissue type matching
between donor and recipient. For adults with malignant and non-malignant disease, cord
blood is a good alternative source of HSCs to bone marrow or cytokine (granulocyte
colony-stimulating factor) stimulated peripheral blood stem cells. Unrelated cord blood
transplants result in good outcome in children transplanted in remission and with inborn
errors of metabolism and immune deficiencies, which in part relates to the small size of
these patients.
Essential preclinical studies proved a higher percentage of CD34' CD38-cells in
UCB compared with BM, suggesting that more primitive progenitors may be abundant
in neonatal blood [35]. The same might apply for the presence of MSCs or progenitor
cells. Lee et al. [36] reported it is possible to obtain clonally expanded MSCs from
umbilical cord blood with remarkable potential to differentiate into multiple lineages of
mesodermal and nonmesodermal origin.

Telomere Length is Linked to Limited Proliferation Capacity
Telomeres, the terminal guanine-rich sequences of chromosomes, are structures
that function in the stabilization of the chromosome during replication by protecting the
chromosome end against exonucleases. Telomeres are reduced in length during each
cell division. The gradual decrease in telomere length may function as a timing
mechanism that, when reaching a critical length, signals a cell to stop dividing and to
enter cellular senescence. A clear correlation is seen between replicative capacity and
the initial telomere length in normal somatic cells [37]. Human telomeres, which consist
of repeats of the sequence TTAGGG at the chromosome ends, are elongated by the
ribonucleoprotein enzyme telomerase. Telomerase is preferentially expressed in
germline cells, immortalized cells, and in most tumor cells. Thus, in these cells,
telomerase apparently balances the telomere loss with de novo synthesis of telomeric
DNA. In contrast, telomerase is not expressed in most human somatic cells, and the
cells become senescent when progressive telomere shortening during each cell division
reaches a threshold telomere length. Cells in regenerative tissues such as skin and bone
also could decrease their telomere length and replicative capacity with aging, because
their progenitors also divide and decrease their telomere length throughout the life span
of cells. Thus, during aging, the cumulative numbers of senescent progenitor or mature
cells in renewable tissue may contribute to disorders in tissue repair or remodeling,
resulting in organismic senescence [37].
With advancing age, a progressive and age-dependent bone loss can be observed in

patients with systemic or localized bone diseases. This bone loss may be caused by, at
least in part, a reduced bone mass that most likely results from inadequate bone
formation by osteoblasts. The rate of bone formation is largely determined by the
number of osteoblasts, which in turn is determined by the rate of replication of
progenitors (MSCs) and the life span of mature cells. Changes in either the replicative
potential or the life span of osteoblasts may alter the rate of bone formation.

Applications of Mesenchymal Stem Cells in Tissue Engineering and Regenerative
Medicine
Bone is a dynamic, highly vascularized tissue with a unique capacity to heal and
remodel without leaving a scar. These properties, together with its capacity to rapidly
mobilize mineral stores on metabolic demand, make it the ultimate smart material. Its
main role is to provide structural support for the body. Furthermore the skeleton also
serves as a mineral reservoir, supports muscular contraction resulting in motion,
withstands load bearing and protects internal organs [38]. Hence, it is logical to say that
major alterations in its structure due to injury or disease can dramatically alter one's
body equilibrium and quality of life.
The demand for treatment strategies of musculoskeletal tissues is continuously
growing, especially considering the increasing number of elder people with
degenerative diseases of the skeletal system. In the USA alone, the population over the
age of 65 is expected to double and the number of people over 85 is projected to
quadruple in the next 20 years [39]. Every year 110,000 Americans suffer nonhealing

long bone defects. For classical skeletal reconstruction, orthopaedic surgeons have
applied autologous (derived from the patient's own cells) or allogenic (same species,
but not patient's own cells) tissues and artificial alloplastic implants. The success of
such surgeries is limited due to the donor site morbidity of autologous grafts, the
irnmunogenicity of allogenic grafts and loosening of the alloplastic implants [40].
Although major progresses were done in the field of bone regenerative medicine
during the years, current therapies, such as bone grafts, still have several limitations.
Moreover, and despite of the fact that materials science technology has resulted in clear
improvements in the field of bone substitution medicine, no adequate bone substitute
has been developed. Thus, most of the severe injuries related to bone are still
unrecoverable or not adequately treated.
Promising new bioengineering technologies, such as tissue engineering, which is
an interdisciplinary field of physicians, engineers and scientists, may provide novel
tools for reconstructive surgery and will probably help to overcome the previously
mentioned disadvantages. Tissue engineering allows the design of functionally active
cells within supportive bio-scaffolds combined with the controlled delivery of growth
factors to promote the development of new tissues such as cartilage and bone for the
restoration of pathologically altered tissues [41]. Consequently, common tissue
engineering principles focus on: (1) healthy cells, which have to be nonimmunogenic,
easy to isolate and highly responsive to distinct environmental cues, (2) suitable carriers
for the in vitro cell differentiation and subsequent transplantation, and (3) a set of
defined bioactive molecules driving the process of differentiation and maturation. Bone

tissue engineering requires the appropriate osteoprecursor cells and a host of
osteoinductive factors.
The proliferation capacity of many adult organ-specific cells is low and longterm in vitro cultivation, in particular, reduces their functional quality. These are the
reasons why so much attention has been drawn to pluripotent embryonic (ES) or
multipotent stem cells. Multipotent stem cells, such as mesenchymal stem cells (MSCs)
are promising candidates for tissue repair because of their differentiation potential and
their capacity to undergo extensive replication. Sources of these cells include the
embryo, umbilical cord blood, amniotic fluid and certain sites in adults such as the
central nervous system (CNS) and bone marrow. More than 100 million Americans
suffering from diseases might profit from stem cell-based tissue engineering
applications. Mesenchymal stem cells induced into osteoblasts hold promise for healing
musculoskeletal disorders such as non-union fractures and osteoporosis (Figure 1).
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One of the early problems regarding the study of MSCs was the high
heterogeneity of whole bone marrow cultures. In 1992 Haynesworth et al. [42]
described a method that, although did not completely solve the heterogeneity problems
of the cultures, was able to overcome some of the problems of previous techniques.
The methodology is based on the separation of the MSCs through gradient
centrifugation, after which cells were plated on tissue culture plastic. In these
conditions they presented similar fibroblastic morphology and the same characteristics
of the cells described by Friedenstein [24]. In later studies published by several authors
these cells were able to develop into distinct terminal and differentiated cells including
bone, cartilage, fat, and tendon.
Besides its differentiation potential, MSCs present other important properties.
As described by Bruder et al. [20] they can be extensively expanded in vitro. Pittinger
et al. [18] also showed that with an increased number of passages they did not
spontaneously differentiate. Furthermore it has been suggested that these cells may
possess immunosuppressive effects which may render them either "immune privileged"
or perhaps immunosuppressive in vivo, which would make them suitable for allogenic
or xenogenic transplantation.
Although MSCs have several advantages regarding their use for tissue
engineering, there are still some issues that need to be addressed. For instance, it is
known that the percentage of MSCs present in the bone marrow is very low (1 in every
100,000 cells) [43] which would make the expansion time consuming. New expansion
methods can be the solution to obtain the amount of cells necessary to be useful in

clinical applications. The differentiation capability of donors from different ages also
needs to be addressed. It has been shown that the numbers as well as the differentiation
potential of MSCs was somewhat diminished when these were isolated from elderly
patients [30,44]. Finally, like in the ES cells, the knowledge regarding the mechanisms
and pathways that lead to the final osteogenic differentiation is still scarce.
Overall it can be said that, for now, MSCs represent more advantages than ES
cells for use in bone tissue engineering. The former are already in clinical trials for
certain applications, including bone tissue engineering while the latter still have a long
way until they reach that stage.

Focus of current research
The major focus of the following research will be the isolation and
characterization of mesenchymal stem cells derived from both adult bone marrow and
umbilical cord blood. Using a novel isolation method based on positive and negative
selection we look to isolate a more homogeneous MSC population when compared to
the widely used plastic adherence method. We hypothesize that with the use of specific
cell-surface markers we can remove unwanted cells from the samples and extensively
grow, in vitro, a purer population of mesenchymal stem cells. Furthermore we will look
at the potential of these isolated MSCs to differentiate into mature, bone producing
osteoblasts. Using the techniques of confocal microscopy, cellular staining, and RTPCR we will show that MSCs, upon stimulation, can differentiate into osteoblasts
capable of being used for bone tissue engineering applications.

CHAPTER 2

This chapter will focus on the isolation and characterization of a homogeneous
mesenchymal stem cell (MSC) population from both adult bone marrow and umbilical
cord blood using a novel isolation method. We hypothesize that an immuno-depletion
method against specific cell-surface markers will increase MSC homogeneity compared
to the widely used plastic adherence method.

CHAPTER 2
ISOLATION AND CHARACTERIZATION OF MESENCHYMAL STEM
CELLS FROM HUMAN BONE MARROW AND UMBILICAL CORD BLOOD
ABSTRACT
This study compares the isolation and characterization of mesenchymal stem
cells from two different sources, bone marrow and umbilical cord blood. In order to
study the molecular mechanisms and therapeutic potential of MSCs, a homogeneous
cell population must be isolated and characterized. A novel isolation technique
developed by our lab is compared to the frequently used method of plastic adherence.

With the use of irnmuno-depletion we removed unwanted cells from our samples by
attaching paramagnetic antibodies targeted to cells to be removed. Our results show
that after 4 weeks of proliferation in MSC expansion media, the immuno-depleted
MSCs were 99%double positive for antibodies CD44 and CD105 which are highly
specific for multipotent MSCs. Cells isolated using the plastic adherence method were
only 43%double positive for the two MSC-specific markers.
With a homogeneous population of MSCs we looked at the similarities and
differences between MSCs isolated from adult bone marrow and umbilical cord blood.
The morphology of the MSCs from each source varied slightly as the adult bone
marrow (ABM)-derived MSCs were all thin with long spindles while umbilical cord
blood (UCB)-derived MSCs ranged from flat, round cells to thin, elongated MSCs.

However, upon confluency, both ABM-derived and UCB-derived MSCs displayed
homogeneous fibroblastoid morphologies with long protrusions at both poles.

INTRODUCTION
Mesenchymal stem cells (MSCs) can be enriched from whole bone marrow and
umbilical cord blood by isolation of fibroblastoid cells via their preferential attachment
to tissue culture plastic. Although this fractionation method yields a phenotypically and
functionally heterogeneous fibroblastoid cell population [45,46] it has been used
widespread due to the lack of specific antigens for direct isolation of MSCs from both
sources. MSC colonies isolated by adherence to the plastic culture plate are
heterogeneous, likely containing osteoblasts and/or osteoprogenitor cells, fat cells,
fibroblasts, reticular cells, macrophages, endothelial cells, and a fraction of blood cells
and hematopoietic stem cells [47]. Hematopoietic cells constitute a large percentage of
plastic adherent murine marrow cultures due to their ability to adhere directly to tissue
culture plastic as well as bind to fibroblastoid (stromal) cells via engagement with
adhesion molecules, cytokine receptors, and extra cellular matrix proteins [48-511.
Moreover, hematopoietic cells persist in these cultures even after serial passage due to
the ability of stromal cells to support granulopoiesis and B cell lymphopoiesis even in
the absence of exogenous growth factors and cytokines [46,52]. Several methods have
been reported to separate fibroblastoid and hematopoietic cells in plastic adherent cell
cultures. Wang and Wolf [53] demonstrated that when bone marrow cells are plated at
very low density, fibroblastoid colonies arise that are devoid of hematopoietic cell
types. However, the method is impractical as a purification scheme because it yielded
only 27 fibroblastoid colonies of 5 or more cells from a total of 200 culture dishes.
Modderman et al. [54] reported that repeated exposure of plastic adherent bone marrow

cultures to the cytotoxin potassium thiocyanate selectively poisoned macrophages and
other hematopoietic cell types, producing an enriched population of fibroblastoid cells.
However, the authors failed to determine if the later contained a pool of progenitors
capable of multi-lineage mesenchymal cell differentiation.
In the absence of a reliable purification scheme most laboratories continue to

employ the method of plastic adherence to isolate MSCs, despite its limitations.
Accordingly, the engraftment or therapeutic potential of MSCs has been evaluated in
vivo by administering the plastic adherent cell fraction of bone marrow to experimental
animals [55-571. Since this population includes hematopoietic potential in vivo the
aforementioned studies are confounded in that they do not provide a direct measure of
the contribution made by MSCs to the experimental outcome.

Isolating a Homogeneous MSC Population from Umbilical Cord Blood (UCB) and
Adult Bone Marrow (ABM)
Our lab has formulated a protocol based on immuno-depletion and positive
selection of specific cell-surface markers to prepare primary cultures with a more
homogeneous cell population of BM- and UCB-derived MSCs. Bone marrow and cord
blood samples are enriched by negatively selecting for a variety of hematopoietic and
monocyte cell surface markers with the use of density gradient cocktails and magnetic
cell sorting. The samples are then positively selected for CD271, also known as

LNGFR (low affinity nerve growth factor receptor), which has been shown to be a
marker for the enrichment of nonhematopoietic stem cells. The cells are gown in
supplemented media and when compared to MSCs isolated using the plastic adherence

method, the cells isolated with our protocol are shown, with the use of flow cytometry,
to be a more homogeneous MSC population.

Purpose of the Present Study
The goal of this study was to compare the isolation and characterization of
mesenchymal stem cells from two different sources, bone marrow and umbilical cord
blood. Harvesting cells from bone marrow, the most common source, is an invasive
procedure and it has been demonstrated that the number and the differentiating potential
of bone marrow MSCs decreases with age [58]. Umbilical cord blood contains young,
highly proliferative cells able to differentiate into the same lineages as MSCs derived
from adult bone marrow.
A comparison of these two MSC sources was made by isolating samples from
both UCB and BM using our novel isolation technique. We hypothesize that an
irnmuno-depletion method against specific cell-surface markers will increase MSC
homogeneity compared to the widely used plastic adherence method.

MATERIALS AND METHODS

Cells and cell culture
Isolation of mesenchymal stem cells from bone marrow

Bone marrow aspirates were obtained from the iliac crest of normal patients (4165 years old) after informed consent and under a protocol approved by the VCU
Institutional Review Board (VCU IRB# 3966). About 10-20 mL bone marrow aspirate
were collected in a syringe containing heparin to prevent coagulation. The
mononuclear cell fraction was isolated from red cells by density centrifugation over
Histopaque 1077 (Sigma, St. Louis, MO). Magnetic-activated cell sorting (MACS) was
performed removing hematopoietic and monocyte progenitor cells from the BM sample.
CD 34' hematopoietic progenitor cells were magnetically labeled using MACS CD34
MicroBeads (Miltenyi Biotec, Auburn, CA). The magnetically labeled cells were
removed by positive' selection columns in the magnetic field of the MiniMACS
Separator (Miltenyi Biotec, Auburn, CA). The same process was repeated with the use
of a MACS Monocyte Isolation Kit which removed the monocyte lineage (CD3, CD7,
CD14, CD56, and CD123) cells from the sample. The samples were then positively
selected for CD27 1, also known as LNGFR (low affinity nerve growth factor receptor)
with the use of a CD271 (LNGFR)-FITC and Anti-FITC MicroBeads MACS kit
(Miltenyi Biotec, Auburn, CA). The cells were plated in expansion medium at a density
of lo5 cells/cm2 in T25 tissue culture flasks (Nunclon, Roskilde, Denmark).

Isolation of mesenchymal stem cells from umbilical cord blood
Cord blood was collected into a sterile collection bag after informed consent of
the mother using the guidelines approved by the VCU Institutional Review Board (VCU
IRB# 2574). Blood was collected using a standard procedure with syringes containing
L-heparin as anticoagulant. Mononuclear cells were separated from red cells by
sedimentation with a solution of hydroxyethyl starch followed by density centrifugation
over Histopaque 1077 (Sigma, St. Louis, MO). MSCs are enriched by depleting CD34+
,CD14+, CD3+, CD7+, CD16+, CD19+, CD56+, CD123+ and glycophorin+ cells

using indirect MACS isolation kits as previously described for bone marrow (Miltenyi
Biotech, Auburn, CA). The samples are then positively selected for CD27 1 with the
use of a CD27 1 (LNGFR)-FITC and Anti-FITC MicroBeads MACS kit (Miltenyi
Biotec, Auburn, CA). The cells were plated in expansion medium at a density of lo5
cells/cm2in T25tissue culture flasks (Nunclon, Roskilde, Denmark).

MSC Expansion Media
Expansion medium consists of Dulbecco's modified eagle medium (DMEM; Gibco,
Grand Island, NY) containing 20% fetal bovine serum (FBS, Gibco), O.4pVml
gentamycin (Gibco), 2mM L-glutamine (Gibco), and 4ngIml basic-fibroblast growth
factor (P-FGF; Sigma). The imrnunodepleted cells were incubated in a humidified
atmosphere at 37OC with 5%CO2,and the medium was changed every 7 days until the

cells reached 80% confluence. Once adherent cells reached approximately 80%
confluence, they were detached with Versene-EDTA (ethylenediaminetetraacetic acid;
Carnbrex, Walkersville, MD), washed with phosphate-buffered saline (PBS; Gibco,
Grand Island, NY), centrifuged at 1000 rpm (82 x g) for 5 minutes, and replated at 1:3
in 3 x T7' tissue culture flasks under the same culture conditions. Cells were allowed to
proliferate for 4-5 weeks in MSC expansion media and were tested for specific cellsurface markers at varying intervals throughout.

Flow Cytometry
After 10, 14,28, and 42 days the cells were analyzed for the presence of specific
cell surface markers. Cells were removed from tissue culture flasks adding VerseneEDTA (5mL per T7' flask) and incubating for 5 minutes at 37 "C. About 1x10'
cells/sample to be tested were removed and centrifuged for 5 minutes at 10,000 rpm.
Supernatant was decanted and cells were resuspended in PBS solution. lml of 1x10'
cells/ml was transferred to a 12 x 75 glass disposable culture tube (Fischer Scientific).
Glass tubes were then centrifuged at max speed (16,000 x g) for 2 minutes. PBS was
decanted off and specific antibodies conjugated to either phycoerythrin (PE) or
fluorescein isothiocyanate (FITC) were added sequentially. lop1 of IgGI:FITC and
lop1 of IgG1:PE were added to each sample and run as isotype controls. CD105 and
CD44 were used as positive MSC markers. lop1 of 105:PE and lop1 of 44:FITC were
added. As a negative control, non-mesenchymal markers against CD45 and CD33 were
used to test for hematopoietic cells. lop1 of 45:PE and 10pl of 33:FITC were added to

tubes. Table 1 summarizes all information on antibodies used in the study. Tubes were
quickly vortexed then incubated at 4 OC for 1 hour. After incubation, lml of PBS was
added to each tube, tubes were vortexed, and spun for 2 minutes at max speed (14,100 x
g) as a wash. The wash step was repeated and PBS decanted. 0.5ml of PBS was added
to each tube, vortexed, and filtered through a 0.2 pm filter paper. Samples were put on
ice and brought to the Flow and Imaging Cytometry Facility (Sanger Hall 2-012
Richmond, Virginia) to be analyzed.

STRO-1

Primary host
animal
Mouse lgG2b
anti-human
Mouse IgG1 antihuman
Mouse IgG1 antihuman
Mouse IgG1 antihuman
Mouse IgM antihuman

lgGl lsotype Control

Mouse

lgG, lsotype Control

Mouse

IgM lsotype Control

Mouse

Antibody
CD44
CD105
CD33
CD45

Secondary antibody

Supplier

FITC-conjugated
Phycoerythrinconjugated

BD Biosciences

FITC-Conjugated
R-Phycoerythrinconjugated
Anti-mouse IgM FITCconjugated
Anti-mouse IgG FITCconjugated
Anti-mouse
Phycoerythrinconjugated
Anti-mouse IgM FITCconjugated

BD Biosciences

R & D Systems

BD Biosciences
R & D systems; Sigma
R & D systems
R & D systems
Sigma-Aldrich

RESULTS

Isolation and morphological analysis of ABM-derived and UCB-derived
mesenchymal stem cells
It has been demonstrated that plastic adherent cultures elaborated from bone
marrow and umbilical cord blood are an admixture of fibroblastoid and hematopoietic
cell types, the later of which persist in the cultures even after serial passage [46,52, 591.
Accordingly, we developed an isolation scheme to remove unwanted cells from the
samples (Figure 2). The cells were subject to irnmuno-depletion using antibodies
against CD3, CD7,CD14, CD16, CD19, CD34, and CD45, CD56, CD123, and
glycophorin. This procedure removed essentially all hematopoietic and monocytic
lineages from the cell fraction. Cells isolated from adult bone marrow and umbilical
cord blood were grown in the same MSC expansion media consisting of DMEM
supplemented with 20% fetal bovine serum, 0.4plIml gentamycin, 2mM L-glutamine,
and 4nglml P-fibroblast growth factor (P-FGF). All isolated MSC populations
displayed a spindle-shaped morphology (Figure 3). CB-derived MSCs had a
heterogeneous morphology ranging from thin cells to flat round cells. However, upon
contact with surrounding cells both BM-derived MSCs and UCB-derived MSCs
changed into a homogeneous population and grew larger in size, with long protrusions
at both poles (Figure 3 b,d).

The cell-surface antigen profile of immunodepleted cells was analyzed and
compared with that of plastic adherence isolated cells. Flow activated cells sorting
(FACS) analysis revealed that the imrnunodepleted cells from the positivelnegative
selection method uniformly expressed both CD44 and CD105 (99%) after 4 weeks of
culture in MSC expansion media, but did not express CD33 or CD45 (HSC-specific
markers). This is consistent with the findings for mesenchymal stem cells in the
literature [18]. The cells from the plastic adherence method expressed variable levels
CD44 and CD105 which is characteristic of a heterogeneous cell population (Figure 4).
A comparison between cells isolated from umbilical cord blood and adult bone
marrow was made by looking at the-expressionof MSC cell-surface markers present
after four and five weeks in MSC expansion media. The cell-surface antigen profile of
UCB-derived MSCs was essentially the same as that of BM-derived MSCs with the
bone marrow-derived MSCs expressing slightly higher levels of both MSC antigens
(UCB-derived MSCs 90% doubly positive; ABM-derived MSCs 99% doubly positive)
(Figure 5, Table 2).
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DISCUSSION
A large body of evidence demonstrates that stromal tissue derived from adult

bone marrow and umbilical cord blood contains clonogenic progenitor cells, some of
which are considered to be multi-potent MSCs with the capacity to differentiate into a
range of mesenchymal cell lineages including adipose tissue, bone, cartilage, tendon,
and ligament [43,60]. Despite considerable interest in the potential therapeutic
applications of these cells, there is no well-defined protocol for the prospective isolation
of human MSCs in order to properly study their biological properties prior to cell
culture. Current methodologies for the isolation of MSCs are based upon those initially
described by Friedenstein and colleagues, which rely upon the rapid adhesion of the
stromal progenitor populations to tissue culture plastic and their subsequent rapid
proliferation in vitro [18,24,45]. Such protocols result in a heterogeneous starting
population of adherent bone marrow cells, of which only a minor proportion represent
multipotent MSCs.

In this study we describe the isolation of a minor subpopulation of human
stromal cells that represent a near homogeneous population of multipotent MSCs using
an immuno-depletion isolation technique. This approach entailed removing the
mononuclear cell fraction from red cells by density centrifugation followed by their
separation from contaminating hematopoietic lineages using anti-CD 14, anti-CD34, and
anti-CD45 antibodies conjugated to paramagnetic beads. In order to identify that our
immuno-depletion method resulted in a more homogeneous MSC population we

compared our method with the plastic adherence method. FACS analysis was run after
10 days of culture in MSC expansion media. The expression of CD105 was highly
expressed (>90%) while CD44 was only present in a small percentage of cells (>5%).
After 14 days the irnrnunodepleted cell populations were >90% double positive for both
the MSC-specific cell markers, CD44 and CD105, and as the culture progressed, the
CD44 and CDlO5-positive cells gradually increased until week four where they were
analyzed to be >99% double positive. After 4 weeks it is clear that the population
isolated by immunodepletion is a more homogeneous MSC population. Cells cultured
using the plastic adherence method were analyzed using the same MSC-specific
markers. After 14 days, expression of one of the two markers was seen (87% CD105
positive; 3% CD44vpositive) and only 8% of the cells were double positive. After
progressive culturing, the double positive cells gradually increased until less than half
(3545%) of the cells expressed both CD44 and CD105. This demonstrates that
isolating MSCs using the plastic adherence method does isolate MSCs, but within the
population other cell types must also be present. Tests for specific cell surface markers
expressed on non-mesenchymal cells will help elucidate which other cell types
comprise this heterogeneous population.
FACS analysis demonstrated that we were able to isolate a population of cells
which expressed both MSC-specific markers. The morphology of the cells was similar
in that they both expressed a spindle-shaped structure with numerous protrusions
branching out. UCB-derived MSCs ranged from a flat, rounder shape to a thin,
elongated appearance. As the cells proliferated out and came into contact with each

other, both ABM-derived and UCB-derived MSCs displayed a homogeneous
fibroblastoid structure and became larger with long protrusions at both poles. These
cells showed prolonged proliferative capacity without any morphological changes for
more than 6 passages (over 3 months).
Future studies will entail a comparison of the telomere lengths between adult
bone marrow-derived MSCs and umbilical cord blood-derived MSCs. When studying
MSCs from umbilical cord blood one might assume the proliferation capacity of the
young, healthy cells to be higher than those isolated from older adult bone marrow
samples. Telomere length has been shown to be linked to proliferation capacity in that
older, mature cells have shorter telomeres and lower proliferation rates. The telomere
length between the two samples should differ in that the younger MSCs from cord
blood should have significantly longer telomeres than those isolated from adult bone
marrow. These young, highly multi-potent cells from cord blood could serve as a
replacement for MSCs isolated from bone marrow. These cells might be less
immunogenic in transplant hosts which would lead to a greater therapeutic potential of
these cells. However, MSCs derived from UCB proliferate at least the same or even
better than the ones from ABM, but the yield in extracting them still needs to be worked
out.
MSCs hold promise for future stem-cell based therapy strategies and for tissue
engineering. A major obstacle is the lack of definition and standardization of MSCs.
Our study describes a reliable method to isolate a homogeneous population of MSCs
from both adult bone marrow and umbilical cord blood and characterizes their

morphological and phenotypical characteristics. These cells can now be used to test
their potential for stem cell-based therapies which will in turn contribute to establish a
reliable quality control system for clinical applications.

CHAPTER 3

This chapter will focus on analyzing the potential of the MSCs isolated using
our immuno-depletion method to differentiate into osteoblasts. We will look at the
biology of bone, its remodeling capability, and osteogenesis. We hypothesize that
MSCs isolated from both adult bone marrow and umbilical cord blood by the immunodepletion method and cultured in osteogenic media will differentiate into functional
osteoblasts.

CHAPTER 3
BIODEVELOPMENT OF OSTEOBLASTS FROM MESENCHYMAL STEM
CELLS DERIVED FROM ADULT BONE MARROW AND UMBILICAL CORD
BLOOD

ABSTRACT
In this study I set out to analyze the potential of our isolated MSCs to
differentiate into functional osteoblasts. Mesenchymal stem cells were isolated from
adult bone marrow and umbilical cord blood using the process of immunodepletion as
described in the previous chapter. Cells from each sample were plated on 6-well plates
and induced down the osteogenic pathway by culturing in osteogenic media (10mM Pglycerol phosphate,

M dexamethasone, and 0.2mM ascorbic acid). Time intervals

were set up so after 3 weeks, cells from each ABM or UCB sample had been in
osteogenic media for either 0,7, 14, or 21 days. These time points were selected to
represent progenitor pools of early mesenchymal, osteo-progenitor, and mature cell
stages of osteoblast differentiation.
The results showed that after osteoinduction, cells from both ABM-derived and
UCB-derived MSCs deposited a calcified, mineralized extracellular matrix as was seen
by von Kossa staining. With the use of confocal microscopy the transition of MSCs
into osteoblasts was visualized with fluorescent markers specific for both MSC
progenitor and osteoblast cells. The gene expressions of the cells was also looked at

which confirmed the presence of the osteo-specific molecular markers: Cbfa- 1, osterix,
osteocalcin, alkaline phosphatase, and collagen type-I.

INTRODUCTION

Brief insights in bone biology
Bone tissue in the adult skeleton is arranged in two architectural forms:
trabecular, also called cancelous or spongy bone (around 20% of the total skeleton), and
cortical or compact bone (around 80% of the total skeleton) [61].
The proportions of these two architectural forms differ at various locations in the
skeleton. Cortical bone is almost solid, being only 10% porous, and can be divided into
different subgroups: long bones (femur and tibia), short bones (wrist and ankle), and flat
bones (skull vault and irregular bones) [61]. On the other end, trabecular bone presents
a higher porosity, 50-90%, making its modulus and ultimate compressive strength
around 20 times inferior than that of cortical bone [61]. Trabecular bone is arranged in
a sponge-like form, with a honeycomb of branching bars, plates and rods of various
sizes called trabeculae. It is commonly found in the metaphysis of long bones, covered
by cortical bone, and in the vertebral bodies.
The elaboration, maintenance, and resorption of this remarkable tissue results
from the interaction of three cell types: osteoblasts, osteocytes, and osteoclasts.
Remodeling results from the action of cells that form bone, osteoblasts, and cells that
resorb bone, osteoclasts. Osteoblasts produce an extracellular matrix, osteoid, which is
composed primarily of type I collagen, the balance being non-collagenous proteins.
This matrix is calcified by osteoblasts and during this process the cells become encased

in lacunae within the calcified material and become osteocytes, cells which help to
maintain the structure of the bone. Upon completion of bone formation, a layer of
resting osteoblasts remains on the surface of the bone which is covered by non-calcified
osteoid. Renewal of the osteoblast population results from the differentiation of
osteoprogenitor cells residing in the bone marrow compartment. Defects such as
microfractures are repaired by the coupled action of osteoclasts and osteoblasts.
The overall integrity of bone appears to be controlled by hormones, such as
estrogen and testosterone, and many other proteins secreted by both hematopoietic bone
marrow cells and bone cells. Certain of these cytokines, i.e., growth factors, the
interleukins (interleukin-1, interleukin-6, and interleukin-11), transforming growth
factor-p and tumor necrosis factor-a, play a significant role in controlling the activities
of the osteoblasts and osteoclasts. During the post-menopausal years, women suffer
from accelerated bone loss which can ultimately lead to osteoporosis, a debilitating
disease that affects 20 million women in the United States [39]. The accelerated bone
loss coincides with estrogen withdrawal and an apparent enhancement of the secretion
of cytokines which accelerates osteoclast activity. The increased osteoclast resorption of
bone is coupled to an increased bone formation rate, but the rate of formation lags
behind resorption. The net result is trabecular bone loss and weakening of the bone
structure. Continued bone loss leads to heightened risk of fractures of the vertebrae and
hip. Eventually, the rapid bone turnover ceases, leaving few osteoblasts to form new

bone. The loss of osteoblasts may be related to a decline in the renewing
osteoprogenitor cell population.
Bone development involves a series of different stages that comprise the
proliferation of osteoprogenitor cells at the outset and the differentiation of progenitors
into osteoblasts. The major products of osteoblasts are deposited extracellularly, which
makes for clear visualization of the differentiation process. The extracellular matrix of
bone is calcified and collagenous. Bone-type collagen - type I, designated (a1(1)2a2)is prevalent in several major connective tissues and comprises 85 - 90% of total organic
bone matrix [62].

Osteoblast precursor cells
A series of experiments have been performed that demonstrate the existence of
progenitor cells that give rise to bone, cartilage, muscle, tendon, fat, and a mature
stromal phenotype that supports hematopoietic differentiation. These cells are referred
to as Mesenchymal Stem Cells (MSCs). We have demonstrated a refined technique for
the isolation and extensive subcultivation of human MSCs by the process of
immunodepletion. Purified MSCs have been characterized with respect to their
complement of cell surface and extracellular matrix molecules as well as their secretory
cytokine profile in control and experimental conditions [42]. A series of monoclonal
probes which react with the surface of human MSCs both in situ and in vitro have been
developed. The murine IgM monoclonal antibody (Ab) STRO-1, produced from an
immunization with a population of human CD34+bone marrow cells, can identify a cell

surface antigen by stromal elements in human bone marrow. A STRO-1' subset of cells
is capable of differentiating into multiple mesenchymal lineages including adipocytes,
osteoblasts, and chondrocytes. STRO-1 is a valuable Ab for the identification,
isolation, and functional characterization of human mesenchymal stem cells.

Molecular regulation of osteogenic differentiation
The induction of MSC osteogenesis is a highly programmed process when
illustrated in vitro. Treatment with the synthetic glucocorticoid dexarnethasone (Dex)
stimulates MSC proliferation and supports osteogenic lineage differentiation [63, 641.
Dex promotes differentiation and mineralization by inducing the expression of the main
transcription factors. Organic phosphates, such as P-glycerol phosphate (PGP), also
support osteogenesis by playing a role in the mineralization and modulation of
osteoblast activities [65,66]. Free phosphates can induce the messengerRNA (mRNA)
and protein expression of osteogenic markers such as osteocalcin, and these phosphates
have known effects on the production and nuclear export of key osteogenic transcription
factors. Other supplements, such as ascorbic acid phosphate (vitamin C) and 1,25dihydroxyvitamin D3, are used for osteogenic induction as they are involved in
increasing alkaline phosphatase activity in osteogenic cultures and promoting the
production of osteocalcin [67].

Osteoblast-specific transcription factors
The differentiation of precursor cells into osteoblasts is controlled by a specific
transcription factor, the core binding factor alpha-1 (Cbfa- 1). This member of the
runxlcbfa family of transcription factors was first identified as the nuclear protein
binding to an osteoblast-specific cis-acting element activating the expression of
osteocalcin, the most osteoblast-specific gene. Most of the described osteoblast genes
contain binding sites for the product of the Cbfa-1 gene in their promoter regions and
are thus up regulated upon Cbfa-1 induction [68-701. Consistent with this ability,
genetic experiments identified Cbfa-1 as a key regulator of osteoblast differentiation in
vivo. Indeed, analysis of Cbfa- 1-deficient mice revealed that osteoblast differentiation
is arrested in absence of Cbfa-1, demonstrating both that it is required for this process
and that no parallel pathway can overcome its absence [7 11. Cbfa- 1 was found to be a
critical gene not only for osteoblast differentiation, but also for osteoblast function.
Osterix (Osx), a zinc-finger-containing protein, was shown to be the second
osteoblast-specific transcription factor. Osx-deficient mice lack osteoblasts and do not
form endochondral or intramembranous bones [72]. It is likely that Cbfa-1 and Osx
control different stages of osteoblast differentiation and, as Osx is not expressed in
Cbfa- 1-null mice but Cbfa- 1 is expressed normally in Osx-deficient mice, it has been
suggested that Osx acts downstream of Cbfa-1 [73,74].

Purpose of Present Study

The goal of this study was to analyze the potential of our isolated MSCs to
differentiate into functional osteoblasts. Mesenchymal stem cells were isolated from
adult bone marrow and umbilical cord blood using the process of immuno-depletion as
described in the previous chapter. Cells from each sample were plated on 6-well plates
and induced down the osteogenic pathway by culturing in osteogenic media (10mM Pglycerol phosphate,

M dexamethasone, and 0.2mM ascorbic acid). Time intervals

were set up so after 3 weeks, cells from each ABM or UCB sample had been in
osteogenic media for either 0,7, 14, or 21 days. These time points were selected to
represent progenitor pools of early mesenchymal, osteo-progenitor, and mature cell
stages of osteoblast differentiation. Once the time course was complete, experiments
were run to test the differentiation potential of both adult bone marrow and umbilical
cord blood MSCs into osteoblasts. Confocal microscopy was employed to visualize the
ratio of specific markers for both MSCs and mature osteoblasts. With the use of von
Kossa staining the deposition of a calcified matrix on the surface of cells was evident.
MessengerRNA was also isolated from the cells to check for the presence of specific
osteoblast marker genes by real time-RT-PCR.

MATERIALS AND METHODS

Culture and propagation of MSCs in the undifferentiated state

MSCs were maintained in T75 tissue culture flasks in appropriate MSC culture
media (DMEM, 20% FBS, 0.4pVml gentamycin, 2mM L-glutamine, and 4nglml PFGF). After four passages (four weeks), the MSCs were replated at 2 x 10' per well on
normal 6-well plates (Nunc Inc., Roskilde, Denmark) for experimental analysis. Four 6well plates for each bone marrow and umbilical cord sample were prepared. In each of
the 6-well plates, three of the wells contained sterile square coverslips while the three
remaining wells remained empty. The cells were incubated in a humidified atmosphere
at 37°C with 5%C02, and the media was changed every 4-5 days until cells reached
90% confluency.

Stimulation of osteogenic differentiation

To induce osteogenic differentiation, cells were cultured in MSC culture media
supplemented with lOmM P-glycerol phosphate,

M dexamethasone, and 0.2mM

ascorbic acid (Sigma-Aldrich, St. Louis, MO). Osteogenic media was changed every 45 days. Time intervals were set up so after 3 weeks, cells from each BM or CB sample
have been in osteogenic media for either 0,7, 14, or 21 days.
Von Kossa Staining

A cover slip from each of the time periods was removed and rinsed with
phosphate buffered solution (PBS). The cells were fixed with 10% formalin solution
for one minute then rinsed with PBS. Silver nitrate solution (5%) was added and the
cells were exposed to UV light for 20 minutes. The coverslips were washed in distilled
water three times. Sodium thiosulfate (5%) was added for 5 minutes then again washed
three times with distilled water. The coverslips were then dehydrated, cleared, and
mounted on a slide with proper mounting solution. Images were taken using a light
microscope under a lox magnification.

Immunohistochemistry
Coverslips (one from each time period) were removed from the 6-well plates
and rinsed with phosphate-buffered saline (PBS). Small wells were created on each
cover slip by using an Immedge Pen (Vector Laboratories, Burlingame, CA). Cells were
fixed with ice cold methanol and then rinsed twice with TBS. Cells were permeabilized
and blocked by adding a solution of 0.1% Triton X-100 and 3% normal goat serum
(Vector Laboratories, Burlingame, CA) in TBS and then washed twice with TBS. Slides
were then incubated with primary antibody for one hour. A mouse monoclonal antihuman STRO-1 antibody (R&D Systems, Minneapolis, MN) and a rabbit polyclona.1
antibody to osteocalcin (R&D Systems, Minneapolis, MN) were used at a 1:50
dilutions. The coverslips were washed five times with PBS and the following
fluorophore-conjugated secondary antibodies were incubated for one hour at a dilution
of 1:200 with either chicken anti-rabbit Alexa Fluor 488 (green) or goat anti-mouse IgM

Alexa Fluor 594 (red) (Santa Cruz Biotechnology Inc., Santa Cruz, CA), as specified in
respective figure legends. Coverslips were washed five times with PBS. A fluorescent
DNA binding stain (Hoechst 34580; Molecular Probes, Eugene, OR) was used at a
concentration of Spg/ml and incubated for 30 minutes to visualize nuclei. The
coverslips were then washed five times with PBS. Coverslips were applied to a slide
with an anti-fading medium (Vectashield; Vector Laboratories, Burlingame, CA). Slides
were viewed and images stored using a laser scanning confocal microscope (model
LSM 520 Meta; Carl Zeiss Inc, Thornwood, NY). Each sample was excited using a
405nm, a 488nm, and a 543nm laser. The cells were excited separately by each laser to
eliminate any possible cross-excitation. All images were taken with an optical planar
slice of 1pm thickness using a 64x oil-immersion objective. A composite image was
made by combining the images from the three detection filters. In addition, negative
controls were stained with a secondary antibody only and used to verify the staining
specificity of binding of the secondary antibodies.

Isolation of RNA and DNA Removal

On day 21, total RNA from each time point was extracted with 1mL of TRIReagent (Invitrogen) per well according to the manufacturers instructions. In brief,
after washing cells with sterile PBS, RNA was extracted with TRI-Reagent/chloroform
solution and precipitated with isopropanol. The RNA pellet was washed twice with
75% alcohol before re-dissolving the RNA in RNase-free diethyl pyrocarbonate
(DEPC) water. The RNA sample was cleaned using Messageclean Kit (Nashville,

TN), which removed DNA contaminations from RNA. RNA was quantified by
spectrophotometry using BioRad, Smartspec 3000 (Hercules, CA). Purified RNA
samples from each time period were sent for Real Time-RT-PCR analysis.

Real Time Reverse Transcriptase Polymerase Chain Reaction Analysis
RNA samples were sent to the MCV-VCU Nucleic Acids Research facility to
analyze the expression of specific osteoblast genes. Primer sequences were designed at
the Nucleic Acids Core Lab and were analyzed for their specificity at the National
Center for Biotechnology Information (NCBI). The genes analyzed were: Cbfa- 1,
Osterix, Osteocalcin, Alkaline phosphatase, and Collagen type I. 18s rRNA was used
as an endogenous control.

RESULTS

Immunohistochernical Staining
Immunohistochemical staining was used to detect the presence of mesenchymal
stem cell and osteogenic lineages after 0,7, 14, and 21 days in osteogenic medium. By
looking at markers highly expressed by MSCs (STRO-1) and mature osteoblasts
(Osteocalcin) we were able to follow the cells through the differentiation process into
maturing osteoblasts. Osteocalcin is a protein unique to bone cells that causes the
proper deposition of phosphate and calcium on the organic collagen matrix during new
bone formation. The results showedrhat there was expression of each antibody at
varying levels throughout the differentiation time course. As seen in Figure 6, STRO-1
positive cells (red fluorescence) are expressed in Day 0 and Day 7 bone marrow cells.
By Day 14 however, the intensity of the MSC STRO-1 marker greatly diminishes. The
osteocalcin antibody is minimally present in Day 0 bone marrow cells, but after
induction in osteogenic media the cells begin producing the osteocalcin protein. After
14 days we see very strong staining for osteocalcin and very minimal STRO-1 presence.
As the cells differentiate in the osteogenic media there is a noticeable morphological
change. The cells transition from long spindle-shaped cells (Day 0) to more clustered
cuboidal shaped cells (Day 14). Figure 7 shows another bone marrow sample stained
with STRO-1 and osteocalcin antibodies. Again we see the presence of STRO-1 after 7
days in osteogenic media slowly decreasing until Day 21 where almost no STRO-1 is

present. The osteocalcin fluor shifts in the opposite direction by gradually getting
stronger in intensity as the time in culture progresses. Figure 8 illustrates the
osteogenic differentiation of umbilical cord blood-derived MSCs. At Day 0 the cells
are unquestionably MSCs in a multi-potent state because the STRO-1 Ab is highly
expressed while little to no osteocalcin is seen. Then, as osteoinduction media is
introduced, the cells begin the differentiation process. The cells noticeably change their
shape by bunching together into the distinctive cuboidal shape and start producing high

-

levels of the osteocalcin protein (Fig. 8 Day 14,21).
These images (Figs. 6-8) illustrate that our immunodepletion technique allows
for isolation and expansion of mesenchymal stem cells (MSCs) from adult bone marrow
and umbilical cord blood by the strong presence of the MSC marker STRO-1. They
also demonstrate the ability of these multi-potential MSCs to be differentiated in vitro
into mature, bone producing osteoblast cells after 3 weeks in osteogenic media.

Detection of osteogenic marker expression by RT-PCR analysis
To confirm that the cells were indeed committed to the osteogenic lineage, RTPCR was used to detect the expression of prominent osteo-specific molecular markers:
Cbfa- 1, osterix, osteocalcin, alkaline phosphatase, and collagen type-I. MessengerRNA
was isolated from both adult bone marrow and umbilical cord blood after their
respective time period in osteogenic media, rid of any DNA contamination, and sent to
the Nucleic Acid Research Facility to be analyzed. Results were normalized to an 18s
rRNA endogenous control for each sample.

The expression of osteogenic markers from bone marrow cells is depicted in

Figure 9. The main transcription factor, Cbfa- 1, was highly expressed early in the
differentiation process and its levels remained constant throughout the 3 weeks in
osteogenic culture, while osterix, the transcription factor thought to act downstream of
Cbfa-1, maintains low levels until 14 to 21 days in osteogenic media where its
transcription more than doubles. Osteocalcin levels are present but do not fluctuate
greatly throughout the differentiation process. Alkaline phosphatase and collagen type I
levels both gradually increase over the 3 week differentiation process as more cells are
able to express their genes as .they become mature, fully functional osteoblast cells.
Osteogenic markers expressed by MSCs isolated from umbilical cord blood are
illustrated in Figure 10. Cbfa-1, the main transcription factor, is present but not in such
a high level as the bone marrow cells. Osterix was undetectable on Days 0 and 7 but
Day 14 the late acting transcription factor started to be expressed. After 21 days in
osteogenic media the UCB-derived cells produced an extremely high level of osterix.
Osteocalcin, alkaline phosphatase, and collagen type I were all present, but their levels
did not significantly fluctuate throughout the differentiation process.

Osteogenic differentiation of ABM-derived and UCB-derived MSCs
During the 21 day assay period, MSCs cultured with osteogenic media (10rnM
P-glycerol phosphate,

M dexarnethasone, and 0.2mM ascorbic acid) underwent a

dramatic change in cellular morphology which was accompanied by a significant
increase in calcification and mineralization. Matrix production occurred as early as 7

days after induction and increased with time in culture. After 14 and 21 days of the
culture period, the matrix was mineralizing and the deposition of calcium became
evident by von Kossa staining (Figure 11). No calcification was seen in control
cultures without osteogenic media (Fig. 11a,d). MSCs cultured in osteogenic media
showed a change in their morphology from spindle-shaped to cuboidal in as little as 7
days (data not shown). While control cultures grew as a uniform sheet of cells,
osteogenic cultures began to form multilayered nodular structures as the apparent result
of coalescing cellular aggregates (Fig. 11b,e). At day 21, osteogenic cultures
contained a well-developed uniform sheet of bone-like material which stained heavily
for the presence of calcification (Fig. 11c,f).
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DISCUSSION
This study demonstrates that purified, culture-expanded human MSCs can be
directed into the osteogenic lineage in vitro, culminating in mineralized matrix
production, and thereby establishing a system for studying human osteoblast
differentiation from mesenchymal stem cells. The addition of osteogenic supplements
(1OmM b-glycerol phosphate,

M dexamethasone, and 0.2mM ascorbic acid) to

MSC cultures was capable of inducing rapid osteogenesis as defined by the appearance
of osteoblastic cell morphology, the formation of a mineralized, calcified extracellular
matrix, reactivity with anti-osteogenic cell surface monoclonal antibodies, and the
production of osteo-specific genes.

-

Cultured human MSCs provide a useful model for evaluating the multiple
factors responsible for the step-wise progression of cells from undifferentiated
precursors to secretory osteoblasts, and eventually terminally differentiated osteocytes.
While primary cultures of human MSCs appear morphologically similar to bone
marrow stroma-derived cells, the precise conditions for the cultivation of these cell
types have a profound effect on cell selection and behavior. The cell seeding density,
type of tissue culture plastic, and source of fetal calf serum are known to affect the
developmental potential of cultured cells [42, 751. We maintained cells in the log phase
of growth without allowing them to become confluent and form multilayers, since
differentiation of mesenchymal stem cells is know to be triggered by increasing cell
density [76]. Our protocol for handling human MSCs supports the retention of stem

cell-like properties for many passages, or until such time that the cells are placed in an
inductive environment.

In this study we demonstrate the capability to differentiate MSCs isolated from
adult bone marrow and umbilical cord blood into mature osteoblasts. Setting up a time
course in which the cells were in osteogenic media for different time periods allowed us
to visualize the differentiation stages.
The murine IgM monoclonal Ab STRO-1 can identify a cell surface antigen by
stromal elements on non-hematopoietic cells. A STRO-1' subset of cells is capable of
differentiating into multiple mesenchymal lineages including adipocytes, osteoblasts,
and chondrocytes. STRO-1 is a valuable Ab for the identification, isolation, and
functional characterization of human mesenchymal stem cells. Osteocalcin is a 5800
MW extrahepatic vitamin K dependent protein uniquely expressed by osteoblasts.
Osteocalcin is one of the most abundant proteins in the body and the second most
abundant protein in the skeletal system next to collagen. Osteocalcin functions in
facilitating the binding of calcium ions and hydroxyapatite together to be deposited on
the collagen matrix of developing bones. Osteocalcin is a highly conserved 46-50 amino
acid single chain protein that contains three vitamin K-dependant gammacarboxyglutamic acid residues. The antibody was a polyclonal antibody raised against
the full chain of human osteocalcin. With the use of confocal microscopy we were able
to detect the presence of the mesenchymal stem cell marker (STRO- 1) and osteogenic
marker (osteocalcin) after 0,7, 14, and 21 days in osteogenic medium. This experiment
reconfirmed that we had a homogeneous MSC population able to retain stem cell-like

properties for many passages by the strong presence of the STRO-1 antibody on Day 0
samples. The images detail the transition of MSC progenitor cells into osteoblasts by
characterizing the down regulation of the MSC marker STRO-1 and the up regulation of
the osteoblast protein, osteocalcin. Both ABM-derived MSCs and UCB-derived MSCs
were shown to be induced into osteoblasts. Both cell sources expressed high levels of
the osteocalcin marker and displayed distinct morphological changes after 3 weeks in
osteogenic media.
Using RT-PCR we were able to further demonstrate that the cells were indeed
committed to the osteogenic lineage. The expression of the prominent osteo-specific
molecular markers: Cbfa- 1, osterix, osteocalcin, alkaline phosphatase, and collagen
type-I were detected throughout the differentiation process. Although both bone
marrow and umbilical cord blood produced significant levels of each marker, the adult
bone marrow cells expressed much more compared to their 18s endogenous controls.
This variation is due to the fact that both adult bone marrow and umbilical cord blood
samples were compared to standards from their respected sources.
Staining for calcification using the von Kossa method revealed the deposition of
calcium crystals by the osteoblast cells (Day 14,21). The MSCs in osteogenic culture
formed a continuous interconnected network of mineralized extracellular matrix. The
sheet-like uniformity of this osteogenic response is reminiscent of the intramembranous
ossification which occurs in developing calvariae and long bone diaphyses [77]. The
observation that virtually all cells are involved in the formation of this bone-like
material argues against the selective induction of a limited number of osteoprogenitors

and supports the characterization of this population of cells as homogeneous. The
MSCs which were maintained in MSC expansion media did not express any signs of
calcification. The morphological changes noticeable during the differentiation process
are also of importance. Cells at Day 0 maintained the typical MSC spindle-shaped
morphology while cells induced in osteogenic media clustered together forming bone
nodule-like structures. Both MSCs from ABM and UCB were capable of
differentiating into calcium depositing osteoblast cells.
The isolation of human MSCs and their cultivation described in this study
provide a system for analyzing the events of MSC commitment and osteogenic
differentiation into fully functional secretory osteoblasts and osteocytes. After 3 weeks
in osteogenic media containing lOmM p-glycerol phosphate,

M dexamethasone,

and 0.2mM ascorbic acid, cells isolated from bone marrow and umbilical cord blood
were shown to be fully differentiated, mature osteoblasts. With the ability to examine
the cell and molecular events of differentiation from purified, culture-expanded
multipotent MSCs, we have the capacity to address experimental questions which
cannot be answered using more mature and heterogeneous human osteoblasts.

GENERAL CONCLUSIONS
The data from the two studies presented in this thesis demonstrate that we were
able to isolate a homogeneous population of multipotent MSCs using our
immunodepletion technique. Previous studies with MSCs have isolated cells based on
plastic adherence, which consisted of a heterogeneous population of cells from multiple
lineages. Our method of removing the unwanted cells from the bone marrow or
umbilical cord sample allows for the characterization and therapeutic potential of these
MSCs to be studied without other cell types affecting the results. We also demonstrated
the possibility of MSCs from two different sources to differentiate into mature,
functional osteoblasts. This study confirmed that our starting populations of cells were
indeed multi-potential MSCs capable of being osteoinduced.
MSCs present an exciting progenitor cell source for applications of tissue
engineering and regenerative medicine. Future modalities may include direct
implantation and/or ex vivo tissue engineering, in combination with
biocompatible/biomimetic biomaterials and/or natural or recombinantly derived

biologics. MSCs may also be considered for gene therapy applications for the delivery
of genes or gene products. Another intriguing prospect for the future is the use of
MSCs to create "off-the-shelf' tissue banks. To fully harness the potential of these
cells, future studies should be directed to ascertain their cellular and molecular
characteristics for optimal identification, isolation, and expansion, and to understand the
natural, endogenous roles of MSCs in normal and abnormal tissue functions.
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